News for Achieve Life Sciences, Inc. (ACHV)

Cash, Cash Equivalents, and Marketable Securities: $23.2 million as of March 31, 2025.Total Operating Expenses: $12.9 million for the first quarter of 2025.Net

Achieve Life Sciences is set to file its cytisinicline NDA, targeting nicotine dependence.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ETCompany ParticipantsNicole Jones - Investor RelationsRick...

SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV) a late-stage specialty pharmaceutical company fo

On March 17, 2025, Mark Oki, the Chief Financial Officer of Achieve Life Sciences Inc, purchased 10,000 shares of the company, according to a SEC Filing. Follow

We came across a bullish thesis on Achieve Life Sciences, Inc. (ACHV) on Substack by Rogue Funds. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc.

Operator: Greetings, and welcome to the Achieve Life Sciences Fourth Quarter and Year-End 2024 Earnings Call and Webcast. At this time all participants are in a listen-only mode.

Cash Equivalents and Marketable Securities: $34.4 million as of December 31, 2024, up from $15.6 million on December 31, 2023.Operating Expenses: $12.2 million

Mar 11, 2025 / 12:30PM GMTOperator Greetings and welcome to the Achieve Life Sciences fourth-quarter and year-end 2024 earnings call and webcast. (Operator Inst

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11,

SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV), a late-stage specialty pharmaceutical company

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial

We came across a bullish thesis on Achieve Life Sciences, Inc. (ACHV) on Substack by Jacob Rowe. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc.

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOB

Seattle-based biotechnology company Sana Biotechnology, Inc. (SANA) is up over 227 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for ND

SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV), a late-stage pharmaceutical company focused on

**media[506832]**

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ( ACHV), a late-stage pharmaceutical company dedicated